You searched for "VEGF"
Twenty-five years in retina
In the next of our articles celebrating 25 years of Eye News, the authors look at how the retina specialty has changed over this time and ask what the future might hold. Retinal disease management has benefited from great advances...Effect of minor trauma in eyes with previously undiagnosed angioid streaks
Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...Treatment of diabetic macular oedema
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment
Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...A patient report of pseudoxanthoma elasticum, angioid streaks and choroidal neovascularisation
Angioid streaks (AS) on their own do not cause many problems, with the majority of patients remaining asymptomatic [1]. However, once choroidal neovascularisation (CNV) occurs, the visual prognosis of the patient rapidly declines [2]. Treatment is imperative to try and...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...Initiatives in macular service provision
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
How many injections in nAMD: ranibizumab vs. aflibercept
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy
Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...
Intravitreal functional plasminogen in branch retinal vein occlusion
Branch retinal vein occlusion (BRVO) is the second most common vascular disorder of the eye. Intravitreal injections of anti-VEGF agents and corticosteroids have proven efficacy. Posterior vitreous cortex (PVC) adhesion has been shown to support the development of retinal vein...
International variations in ROP treatment
A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...
